Study Comparing Loncastuximab Tesirine and Rituximab with Standard Immunochemotherapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL) or high-grade B-cell lymphoma with specific genetic changes.
• The cancer must have returned after treatment or not responded to at least one previous treatment.
• Not suitable for stem cell transplantation due to health status, age, or other medical conditions.
• Have measurable cancer as determined by specific imaging tests.
• Provide a tumor sample for testing.
• Have a performance status score of 0 to 2, indicating full activity or some restriction in strenuous activities.
• Have adequate organ function based on specific blood test results.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during and after the study.
• Men must agree to use a condom or practice abstinence during and after the study if their partner is of childbearing potential.

Exclusion Criteria

• Have previously been treated with loncastuximab tesirine or R-GemOx.
• Have allergies to certain antibodies or components of the study drugs.
• Have Burkitt lymphoma.
• Have another active cancer, except for certain non-threatening types.
• Have had a stem cell transplant recently.
• Have active graft-versus-host disease.
• Have an active autoimmune disease.
• Have HIV with certain conditions, such as low CD4 counts or high viral load.
• Have active hepatitis B or C infections.
• Have a history of severe skin reactions.
• Have cancer that has spread to the brain or spinal cord.
• Have significant fluid buildup in the body.
• Are pregnant or breastfeeding.
• Have uncontrolled high blood pressure or serious heart conditions.
• Have had major surgery or certain treatments recently.
• Have used experimental medications or received live vaccines recently.
• Have not recovered from previous treatment side effects.
• Have a heart condition known as long QT syndrome.
• Have any other serious medical condition that could affect participation in the study.
• Have allergies to certain chemotherapy drugs.